Ascelia Pharma AB (publ) (ticker: ACE) (“Ascelia Pharma” or the “Company”) has successfully carried out a directed new share issue of 5,000,000 ordinary shares at a subscription price of SEK 40 per share, subject to the approval of an Extra General Meeting (the “Issue”). The Issue will provide the Company with SEK 200 million before transaction costs. In addition to the Issue, a coordinated sale of 204,070 ordinary shares from participants in the Company’s outstanding incentive program was carried out to cover personal tax effects as well as the subscription price and costs arising from the exercise of the incentive program. 

Press inquiries should be adressed to: